U.S. Markets closed

Plus Therapeutics, Inc. (PSTV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8657-0.0659 (-7.07%)
At close: 04:00PM EST
0.8560 -0.01 (-1.12%)
After hours: 05:58PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.9316
Bid0.8560 x 1200
Ask0.9095 x 1300
Day's Range0.8500 - 0.9594
52 Week Range0.8100 - 5.4200
Avg. Volume3,320,472
Market Cap13.297M
Beta (5Y Monthly)0.39
PE Ratio (TTM)N/A
EPS (TTM)-1.3420
Earnings DateFeb 21, 2022 - Feb 25, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • InvestorPlace

    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

    Happy Friday, trader! We’re starting off the day with an overview of the biggest pre-market stock movers for today! Source: f11photo/ Moving stocks this morning are earnings reports, Covid-19 updates, new regulations in China, and more! Let’s get right into that news below!InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pre-Market Stock Movers: 10 Top Gainers NextPlay Technologies (NASDAQ:NXTP) stock is rocketing more than 39% with the release of its fiscal Q3 2022

  • GlobeNewswire

    Plus Therapeutics to Participate in Upcoming January Conferences

    AUSTIN, Texas, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics, will participate at two virtual conferences in January. EventH.C. Wainwright BioConnect ConferenceDateJanuary 10-13, 2022TimePresentation available on demand sta

  • Benzinga

    Plus Therapeutics Expands Investigational Oncology Drug Pipeline

    Plus Therapeutics, Inc (NASDAQ: PSTV) has entered into an agreement with The University of Texas Health Science Center at San Antonio for a worldwide exclusive license to develop and commercialize novel interventional therapeutics for cancer. “The future of cancer therapy is precise targeting of tumors with the most potent cancer-killing agents while minimizing damage to normal tissues,” said Plus CEO Marc H. Hedrick, M.D. The company said that the transaction would help it expand existing Rheni